ImmunityBio Inc (STU:26CA)
€ 5.662 0.044 (0.78%) Market Cap: 3.87 Bil Enterprise Value: 4.39 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 34/100

NantKwest Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 01:20PM GMT
Antoine Attali

Good morning, everyone. My name is Antoine Attali, and I'm a member of the JPMorgan health care investment banking team. Thank you all for joining us today. It is my pleasure to introduce Dr. Patrick Soon-Shiong, Executive Chairman of NantKwest. (Operator Instructions) Dr. Soon-Shiong, back to you.

Patrick Soon;Shiong

Thank you so much, Antoine. So good morning all. Today, I'm going to spend time explaining how NantKwest and ImmunityBio will enter into the merger and the rationale for the merger as well as the unparalleled late-stage pipeline.

So if you turn to Page 3 -- and obviously, the forward-looking statements you see on Page 2 applies. So if you look at the 2 companies, NantKwest on the left-hand side of the slide, it's a company with a proprietary natural killer cell pipeline and platforms that is clinically advanced at late-stage clinical Phase II trials with proprietary manufacturing capabilities. And the second circle, ImmunityBio, on the other hand, has a broad range of antibody fusion proteins, immunomodulators,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot